Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus

Journal of Endocrinology

Volumn 185, Issue 3, 2005, Pages 539-549

  Gunin, Andrei G ^a   Kapitova, Irina N ^a   Suslonova, Nina V ^a  

^a CHUVASH STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BUTYRIC ACID; ESTRADIOL DIPROPIONATE; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE INHIBITOR; PROGESTERONE RECEPTOR; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM HYPERPLASIA; EPITHELIUM; FEMALE; MITOSIS; MORPHOGENESIS; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ANIMALS; BETA CATENIN; BUTYRATES; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICE; ORGAN SIZE; OVARIECTOMY; RECEPTORS, PROGESTERONE; TRANS-ACTIVATORS; UTERUS;

EID: 21244441901     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06118     Document Type: Article

References (47)

1. Adhikari D, Feroz F, Liefshitz A, Barakat RR, Bertino JR & Banerjee D 2000 Pretreatment of endometrial carcinoma cell lines with butyrate results in upregulation of Bax and correlates with potentiation of radiation induced cell kill. In Vivo 14 603-609.
2. Akhmedkhanov A, Zeleniuch-Jacquotte A & Toniolo P 2001 Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Annals of the New York Academy of Sciences 943 296-315.
3. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC & Vigushin DM 2004 Histone deacetylase inhibitor trichostatin A represses estrogen receptor-alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clinical Cancer Research 10 8094-8104.
4. Ali SH, O'Donnell AL, Mohamed S, Mousa S & Dandona P 2004 Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors. Gynecological Oncology 95 637-645.
5. Archer DF 2004 Neoplasia of the female reproductive tract: effects of hormone therapy. Endocrine 24 259-264.
6. Baek SH, Kioussi C, Briata P, Wang D, Nguyen HD, Ohgi KA, Glass CK, Wynshaw-Boris A, Rose DW & Rosenfeld MG 2003 Regulated subset of G1 &rowth-control genes in response to derepression by the Wnt pathway. PNAS 3245-3250.
7. Bigsby RM 2002 Control of growth and differentiation of the endometrium: the role of tissue interactions. Annals of the New York Academy of Sciences 955 110-117.
8. Billin AN, Thirlwell H & Ayer DE 2000 Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Molecular and Cellular Biology 20 6882-6890.
9. Condon JC, Jeyasuria P, Faust JM, Wilson JW & Mendelson CR 2003 A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. PNAS 100 9518-9523.
10. Cong F, Schweizer L, Chamorro M & Varmus H 2003 Requirement for a nuclear function of beta-catenin in Wnt signaling. Molecular and Cellular Biology 23 8462-8470.
11. Couse JF & Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocrine Reviews 20 358-417.
12. Deligdisch L 2000 Hormonal pathology of the endometrium. Modern Pathology 13 285-294.
13. Deroo BJ, Hewitt SC, Peddada SD & Korach KS 2004 Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology 145 5485-5492.
14. Deschner EE, Ruperto JF, Lupton JR & Newmark HL 1990 Dietary butyrate (tributyrin) does not enhance AOM-induced colon tumorigenesis. Cancer Letters 52 79-82.
15. Emons G, Fleckenstein G, Hinney B, Huschmand A & Heyl W 2000 Hormonal interactions in endometrial cancer. Endocrine Related Cancer 7 227-242.
16. Freeman HJ 1986 Effects of differing concentrations of sodium butyrate on 1,2-dimethylhydrazine-induced rat intestinal neoplasia. Gastroenterology 91 596-602.
17. Fujimoto J, Ichigo S, Hori M & Tamaya T 1996 Alteration of E-cadherin, alpha- and beta-catenin mRNA expression in human uterine endometrium during the menstrual cycle. Gynecological Endocrinology 10 187-191.
18. Fujimoto J, Ichigo S, Hori M & Tamaya T 1998 Expressions of E-cadherin and alpha- and beta-catenin mRNAs in uterine endometrial cancers. European Journal of Gynaecological Oncology 19 78-81.
19. Gunin AG, Sharov AA & Nikolaev DV 2000 Two month glucocorticoid treatment increases estradiol-induced stromal and myometrial cell proliferation in the uterus of ovariectomized rats. European Journal of Obstetrics & Gynecology and Reproductive Biology 88 171-179.
20. Gunin AG, Mashin IN & Zakharov DA 2001 Proliferation, mitosis orientation and morphogenetic changes in the uterus of mice following chronic treatment with both estrogen and glucocorticoid hormones. Journal of Endocrinology 169 23-31.
21. Gunin AG, Emelianov V & Tolmachev AS 2002 Effect of adrenocorticotrophic hormone on the development of oestrogen-induced changes and hyperplasia formation in the mouse uterus. Reproduction 123 601-611.
22. Gunin AG, Emelianov VU, Mironkin IU, Morozov MP & Ivanov VA 2003 Uterine response to estradiol under action of chorionic gonadotropin in mice. International Journal of Gynecological Cancer 13 485-496.
23. Gunin A, Bitter A, Demakov A, Vasilieva E & Suslonova N 2004a Effects of peroxisome proliferator activated receptors-alpha and gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. Journal of Endocrinology 182 229-239.
24. Gunin A, Emelianov V, Mironkin I, Morozov M & Tolmachev A 2004b Lithium treatment enhances estradiol-induced proliferation and hyperplasia formation in the uterus of mice. European Journal of Obstetrics & Gynecology and Reproductive Biology 114 83-91.
25. Henderson BR, Galea M, Schuechner S & Leung L 2002 Lymphoid enhancer factor-1 blocks adenomatous polyposis coli-mediated nuclear export and degradation of beta-catenin. Regulation by histone deacetylase 1. Journal of Biological Chemistry 277 24258-24264.
26. Ing NH & Ott TL 1999 Estradiol up-regulates estrogen receptor-alpha messenger ribonucleic acid in sheep endometrium by increasing its stability. Biology of Reproduction 60 134-139.
27. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ & Lee JS 2004 The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23 1724-1736.
28. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP & Korach KS 2002 Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. Journal of Biological Chemistry 277 8531-8537.
29. Kultima K, Nystrom AM, Scholz B, Gustafson AL, Dencker L & Stigson M 2004 Valproic acid teratogenicity: a toxicogenomics approach. Environmental Health Perspectives 112 1225-1235.
30. Kurtev V, Margueron R, Kroboth K, Ogris E, Cavailles V & Seiser C 2004 Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases. Journal of Biological Chemistry 279 24834-24843.
31. Lupton JR 2004 Microbial degradation products influence colon cancer risk: the butyrate controversy. Journal of Nutrition 134 479-482.
32. Margueron R, Duong V, Castet A & Cavailles V 2004 Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochemical Pharmacology 68 1239-1246.
33. Martin L, Finn CA & Trinder G 1973 Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autoradiographic study. Journal of Endocrinology 56 133-144.
34. Miyamoto S, Baba H, Kuroda S, Kaibuchi K, Fukuda T, Maehara Y & Saito T 2000 Changes in E-cadherin associated with cytoplasmic molecules in well and poorly differentiated endometrial cancer. British Journal of Cancer 83 1168-1175.
35. Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E & Kudo R 1999 Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Molecular Carcinogenesis 25 207-218.
36. Nephew KP, Long X, Osborne E, Burke KA, Ahluwalia A & Bigsby RM 2000 Effect of estradiol on estrogen receptor expression in rat uterine cell types. Biology of Reproduction 62 168-177.
37. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA & Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276 36734-36741.
38. Riester D, Wegener D, Hildmann C & Schwienhorst A 2004 Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates. Biochemical and Biophysical Research Communications 324 1116-1123.
39. Saito S, Crissman HA, Nishijima M, Kagabu T, Nishiya I & Cram LS 1991 Flow cytometric and biochemical analysis of dose-dependent effects of sodium butyrate on human endometrial adenocarcinoma cells. Cytometry 12 757-764.
40. Sakai N, Maruyama T, Sakurai R, Masuda H, Yamamoto Y, Shimizu A, Kishi I, Asada H, Yamagoe S & Yoshimura Y 2003 Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. Journal of Biological Chemistry 278 16675-16682.
41. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG & Wilkinson EJ 1994 Histological typing of female genital tract tumours. In International Histological Classification of Tumours, 2nd edn, pp. 13-18. Geneva: WHO.
42. Sivridis E, Giatromanolaki A, Koukourakis M & Anastasiadis P 2001 Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Archiv 438 470-477.
43. Sun JM, Chen HY & Davie JR 2001 Effect of estradiol on histone acetylation dynamics in human breast cancer cells. Journal of Biological Chemistry 276 49435-49442.
44. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I & Koeffler HP 2004a Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clinical Cancer Research 10 1141-1149.
45. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I & Koeffler HP 2004b Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101 2760-2770.
46. Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T, Kato H, Furugen Y, Yoshida K, Kato K & Wake N 2001 Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. International Journal of Cancer 94 257-267.
47. Wilson MA, Ricci AR, Deroo BJ & Archer TK 2002 The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo. Journal of Biological Chemistry 277 15171-15181.